Preclinical and clinical evaluation of a new virosomal intranasal influenza vaccine

International Congress Series

Volumn 1219, Issue C, 2001, Pages 969-978

  Glück, Reinhard ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

Influenza vaccine; Intranasal; Virosomal

Indexed keywords

EID: 23544450952     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00654-9     Document Type: Article

References (14)

1. CDC Atlanta. Prevention and control of influenza: Part I, vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48:No. RR-4 (1999), 1–28.
2. Wright, P.F., Cherry, J.D., Foy, H.M., Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children—a multicentered evaluation of dosage and safety. Rev. Infect. Dis. 5 (1983), 758–764.
3. Ershler, W.B., Influenza vaccination in the elderly: can efficacy be enhanced?. Geriatrics 43 (1988), 79–83.
4. Couch, R.B., Keitel, W.A., Cate, T.R., Improvement of inactivated influenza vaccines. J. Infect. Dis. 176:Suppl. 1 (1997), 38–44.
5. Zei, T., Neri, M., Ioro, A.M., Immunogenicity of trivalent subunit and split influenza vaccines (1989–1990) winter season in volunteers of different age groups. Vaccine 9 (1991), 613–617.
6. McGhee, J.R., Kiyono, H., New perspectives in vaccine development: mucosal immunity to infections. Infect. Agents Dis. 2 (1993), 55–73.
7. Holmgren, J., Mucosal immunity and vaccination. FEMS Microbiol. Immunol. 89 (1991), 1–10.
8. Glück, R., Mischler, R., Finkel, B., Que, J.U., Scarpa, B., Cryz, S.J. Jr., Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344 (1994), 160–163.
9. Conne, P., Gauthey, L., Vernet, P., Althaus, B., Que, J., Finkel, B., Glück, R., Cryz, S.J. Jr., Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15 (1997), 1675–1679.
10. Walker, R.I., New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12 (1994), 387–400.
11. Baqar, S., Burgeois, A.L., Schultheiss, P.J., Walker, R.I., Rollins, D.M., Haberberger, R.L., Pavloskis, O.R., Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 13 (1995), 22–28.
12. Hashigucci, K., Ogawa, H., Ishidate, T., Yamashita, R., Kamiya, H., Watanabe, K., Hattori, N., Sato, T., Suzuki, Y., Nagamine, T., Aizawa, C., Tamura, S., Kurata, T., Oya, A., Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14 (1996), 113–119.
13. Cusi, M.G., Lomagistro, P.E., Valassino, M., Valensin, P.E., Glück, R., Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combinated influenza virosomal vaccine. Vaccine 18 (2000), 2838–2842.
14. F. Swaby, L. Kelly, R. Lambkin, J. Oxford, The efficacy of a test vaccine in the ferret influenza model when challenged with homologous virus. Internal SSVI Final Report dated May 7, 1999.